251 related articles for article (PubMed ID: 37325955)
1. Androgens and Selective Androgen Receptor Modulators to Treat Functional Limitations Associated With Aging and Chronic Disease.
Bhasin S; Krishnan V; Storer TW; Steiner M; Dobs AS
J Gerontol A Biol Sci Med Sci; 2023 Jun; 78(Suppl 1):25-31. PubMed ID: 37325955
[TBL] [Abstract][Full Text] [Related]
2. Selective androgen receptor modulators as function promoting therapies.
Bhasin S; Jasuja R
Curr Opin Clin Nutr Metab Care; 2009 May; 12(3):232-40. PubMed ID: 19357508
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging.
Bhasin S; Calof OM; Storer TW; Lee ML; Mazer NA; Jasuja R; Montori VM; Gao W; Dalton JT
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):146-59. PubMed ID: 16932274
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator.
Zhang X; Allan GF; Tannenbaum P; Sbriscia T; Linton O; Lai MT; Haynes-Johnson D; Bhattacharjee S; Lundeen SG; Sui Z
J Steroid Biochem Mol Biol; 2013 Mar; 134():51-8. PubMed ID: 23098693
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the growing public interest in selective androgen receptor modulators.
Efimenko IV; Chertman W; Masterson TA; Dubin JM; Ramasamy R
Andrologia; 2021 Dec; 53(11):e14238. PubMed ID: 34510504
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery.
Segal S; Narayanan R; Dalton JT
Expert Opin Investig Drugs; 2006 Apr; 15(4):377-87. PubMed ID: 16548787
[TBL] [Abstract][Full Text] [Related]
7. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
8. Anabolic applications of androgens for functional limitations associated with aging and chronic illness.
Bhasin S; Storer T
Front Horm Res; 2009; 37():163-182. PubMed ID: 19011296
[TBL] [Abstract][Full Text] [Related]
9. Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review.
Machek SB; Cardaci TD; Wilburn DT; Willoughby DS
Steroids; 2020 Dec; 164():108753. PubMed ID: 33148520
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.
Jones A; Hwang DJ; Duke CB; He Y; Siddam A; Miller DD; Dalton JT
J Pharmacol Exp Ther; 2010 Aug; 334(2):439-48. PubMed ID: 20444881
[TBL] [Abstract][Full Text] [Related]
11. Selective androgen receptor modulators for frailty and osteoporosis.
Kilbourne EJ; Moore WJ; Freedman LP; Nagpal S
Curr Opin Investig Drugs; 2007 Oct; 8(10):821-9. PubMed ID: 17907058
[TBL] [Abstract][Full Text] [Related]
12. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile.
Rosen J; Negro-Vilar A
J Musculoskelet Neuronal Interact; 2002 Mar; 2(3):222-4. PubMed ID: 15758439
[TBL] [Abstract][Full Text] [Related]
13. Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials.
Fonseca GWPD; Dworatzek E; Ebner N; Von Haehling S
Expert Opin Investig Drugs; 2020 Aug; 29(8):881-891. PubMed ID: 32476495
[TBL] [Abstract][Full Text] [Related]
14. Hormone treatment and muscle anabolism during aging: androgens.
Dillon EL; Durham WJ; Urban RJ; Sheffield-Moore M
Clin Nutr; 2010 Dec; 29(6):697-700. PubMed ID: 20452103
[TBL] [Abstract][Full Text] [Related]
15. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting.
Grinspoon S; Corcoran C; Lee K; Burrows B; Hubbard J; Katznelson L; Walsh M; Guccione A; Cannan J; Heller H; Basgoz N; Klibanski A
J Clin Endocrinol Metab; 1996 Nov; 81(11):4051-8. PubMed ID: 8923860
[TBL] [Abstract][Full Text] [Related]
16. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.
Narayanan R; Coss CC; Yepuru M; Kearbey JD; Miller DD; Dalton JT
Mol Endocrinol; 2008 Nov; 22(11):2448-65. PubMed ID: 18801930
[TBL] [Abstract][Full Text] [Related]
17. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.
Cardaci TD; Machek SB; Wilburn DT; Heileson JL; Harris DR; Cintineo HP; Willoughby DS
Exp Physiol; 2022 Dec; 107(12):1467-1476. PubMed ID: 36303408
[TBL] [Abstract][Full Text] [Related]
18. Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men.
Jasuja R; Ramaraj P; Mac RP; Singh AB; Storer TW; Artaza J; Miller A; Singh R; Taylor WE; Lee ML; Davidson T; Sinha-Hikim I; Gonzalez-Cadavid N; Bhasin S
J Clin Endocrinol Metab; 2005 Feb; 90(2):855-63. PubMed ID: 15522925
[TBL] [Abstract][Full Text] [Related]
19. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
20. Benefits and Risks of Testosterone Treatment in Men with Age-Related Decline in Testosterone.
Rodrigues Dos Santos M; Bhasin S
Annu Rev Med; 2021 Jan; 72():75-91. PubMed ID: 33217248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
